Drug
EC145 clinical trials
Also written Vintafolide and EC145.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses EC145 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)TerminatedPhase 3EndocyteNCT01170650Written as EC145
- Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)CompletedPhase 2EndocyteNCT01002924Written as EC145
- Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung CancerCompletedPhase 2EndocyteNCT01577654Written as EC145
- Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedPhase 2EndocyteNCT00511485Written as Vintafolide
- A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)TerminatedPhase 1EndocyteNCT02049281Written as Vintafolide
- Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)CompletedPhase 2EndocyteNCT00722592Written as Vintafolide
- Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)CompletedPhase 2EndocyteNCT00507741Written as Vintafolide
- Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)CompletedPhase 1EndocyteNCT00308269Written as Vintafolide IV Infusion
- Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)WithdrawnPhase 2EndocyteNCT01953536Written as Vintafolide 2.5 mg